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Abstract: Objective: Insulin therapy is associated with weight gain in patients with type 2 diabetes mellitus (T2DM). 
Several peptides are implicated in appetite control. We evaluated the effects of insulin-induced improved glycaemic con-
trol on leptin, adiponectin, ghrelin, neuropeptide Y (NPY) levels and patient characteristics.  
Method: Consecutive T2DM patients (n = 90) were divided into 2 groups: Group A: 45 insulin-naïve uncontrolled (glyco-
sylated haemoglobin A1c; HbA1c >7%) patients on oral hypoglycaemic agents (OHAs) who converted to insulin mono-
therapy. Group B: 45 well-controlled (HbA1c <7%) patients on OHAs. Both groups were monitored at baseline, 3 and 6 
months. Males and females were analyzed separately because some hormone levels differ between genders.  
Results: In both genders, insulin therapy (Group A) was associated with significant (p = 0.003 to <0.001) increases in 
weight, body mass index and leptin levels and significant decreases in glucose, HbA1c and NPY levels. In male insulin-
treated patients a significant increase in adiponectin levels (p = 0.008) was observed. There were significant correlations 
(p = 0.016 to <0.001) between leptin levels, waist circumference and body fat in all patient groups, except group B males.  
Conclusion: Changes in leptin, adiponectin and NPY levels may occur after insulin-induced improved glycaemic control. 
These changes may be influenced by gender, weight, body fat and HbA1c. 
Keywords: Gender, glycosylated haemoglobin A1c, insulin, type 2 diabetes mellitus, weight gain.  
INTRODUCTION  
  In patients with type 2 diabetes mellitus (T2DM) tight 
glycaemic control with either intensive insulin therapy or 
sulfonylureas has been associated with weight gain [1, 2]. 
However, insulin-treated patients gained more weight com-
pared with those on oral hypoglycaemic agents (OHAs) [2]. 
  The underlying mechanisms causing insulin-induced 
weight gain are only partly understood and include (apart 
from the correction of dehydration in some cases) the ana-
bolic effects of insulin, stimulation of lipogenesis, suppres-
sion of hepatic glucose production, reduction of basal meta-
bolic rate and elimination of glycosuria [1, 3, 4]. Furthermore, 
fear of hypoglycaemia and a feeling of freedom to eat in   
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patients on insulin therapy may account for additional food 
consumption [3, 5]. On the other hand, a central effect of 
insulin has also been proposed with insulin and leptin resis-
tance leading to reduced satiety signaling to the hypothala-
mus despite overfeeding and hyperinsulinaemia [3, 6]. 
  Nutrients and gastrointestinal hormones like ghrelin are 
considered as short-term signals that influence food intake 
[7]. In contrast, insulin and leptin act as long-term regulators 
that ensure stability of body weight and adiposity and main-
tenance of energy homeostasis over a more prolonged period 
of time [7]. These regulators transfer information from the 
periphery to the central nervous system, where they modu-
late neuropeptide release which in turn influences appetite 
and energy expenditure [8]. In particular, leptin stimulates 
the expression of anorexigenic neuropeptides and inhibits the 
expression of orexigenic neuropeptides, such as neuropep-
tide Y (NPY), therefore suppressing food intake and enhanc-
ing energy expenditure [8]. Both central and peripheral adi-
ponectin administration reduced body weight via either food 
intake suppression or increased energy expenditure [9]. Leptin, Adiponectin, Ghrelin, NPY and Glycaemic Control  The Open Cardiovascular Medicine Journal, 2011, Volume 5    137 
Ghrelin increases NPY expression in the hypothalamus   
and blocks leptin-induced satiety, subsequently leading to 
increased food intake [10].  
  In this pilot study we evaluated the effect of insulin-
induced improvement of glycaemic control on adipokines 
(i.e. leptin and adiponectin), a gut peptide (i.e. ghrelin) and a 
neuropeptide (i.e. NPY) levels, weight parameters, lipids and 
renal function in patients with T2DM. We also considered 
the possible correlations between these variables. 
MATERIALS AND METHODS 
Study Population 
  A total of 90 consecutive patients with T2DM were re-
cruited from the Diabetes Outpatient Clinic, AHEPA Uni-
versity Hospital, Thessaloniki, Greece. The study population 
was divided into 2 groups: Group A consisted of 45 insulin-
naïve poorly controlled (glycosylated haemoglobin A1c; 
HbA1c >7%) patients on OHAs who were converted to insu-
lin monotherapy (2 daily injections of biphasic isophane in-
sulin). Group B consisted of 45 well-controlled (HbA1c <7%) 
patients on OHAs. All patients in group B were taking met-
formin (800 mg, twice daily) and 30 of them were also tak-
ing sulfonylureas, mainly gliclazide (80 mg, 2 or 3 times 
daily). Patients with history of impaired liver or kidney func-
tion, malignancy, endocrinopathy or on corticosteroid treat-
ment were excluded. All women were postmenopausal and 
were not on hormone replacement therapy. 
  Patients on thiazolidinediones were excluded as these 
agents may influence leptin (rosiglitazone) [11], adiponectin 
(rosiglitazone [12] and pioglitazone [13]) and ghrelin levels 
(rosiglitazone) [14]. 
Study Design 
  Both groups were prospectively followed up for 6 
months and monitored on an outpatient basis at baseline, 3 
and 6 months. In the insulin-treated group, dose adjustments 
were based on home blood glucose monitoring. At every 
evaluation, physical examination including weight, height, 
waist circumference (WC) and blood pressure measure-
ments, determination of percentage of body fat by bioimped-
ance analysis (SKYLARK BT-905, Taiwan) and laboratory 
analyses (white cell count (WCC), glucose, HbA1c, creatin-
ine (Cr), uric acid, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyl transpeptidase 
(gamma-GT), creatine kinase (CK), total cholesterol (TC), 
triglycerides (TG), high density lipoprotein cholesterol 
(HDL-C), low density lipoprotein cholesterol (LDL-C), leptin, 
adiponectin, ghrelin and NPY) were performed in all   
patients.  
  Body mass index (BMI = weight/height
2), estimated 
glomerular filtration rate (eGFR) based on the Modification 
of Diet in Renal Disease (MDRD) formula (http://nephron. 
org/mdrd_gfr_si) and creatinine clearance based on the 
Cockroft-Gault formula (http://clinicalculator.com/english/ 
nephrology/cockroft/cca.htm) were also calculated. 
  At baseline, patients were interviewed by a qualified di-
etician. A specific 7-day diet sheet was given to each patient 
at every visit. Daily calorie intake was 500 calories below 
the needs of the patient, taking into account the individual’s 
physical activity. The patients were advised to maintain   
the same diet and level of physical activity throughout the 
study.  
  The study was approved by the local ethics committee 
and informed consent was obtained from all participants. 
Blood Sample Collection and Analysis 
  All blood samples were collected in the morning after an 
overnight fast (water allowed) and divided into 2 samples of 
10 ml each. The first 10 ml were immediately analyzed for 
routine laboratory parameters (WCC, glucose, HbA1c, Cr, 
uric acid, ALT, AST, gamma-GT, CK, TC, TG, HDL-C and 
LDL-C). The second 10 ml, after centrifugation at 4ºC, were 
stored in aliquots at -20ºC until assayed for leptin, total adi-
ponectin, total ghrelin and NPY using commercially avail-
able radioimmunoassay kits (Linco Research Inc., St. Char-
les, MO, USA for leptin, adiponectin and ghrelin; Euro-
Diagnostica Inc., Malmö, Sweden for NPY). It is known that 
ghrelin circulates in 2 forms: octanoylated (acylated) and 
desacylated. Although only acylated ghrelin is bioactive, 
levels of total ghrelin are a good surrogate for those of   
acylated ghrelin because the ratio of the 2 remains constant 
under a wide variety of conditions [15, 16].  
  Regarding intra- and inter-assay variations, for leptin, 
intra-assay variation is 8.3, 4.6, 3.9, 4.7 and 3.4% CV for 5 
varying concentrations of leptin, i.e. 4.9, 7.2, 10.4, 15.7 and 
25.6 ng/ml, respectively, whereas inter-assay variation is 6.2, 
5.0, 4.7, 3.0 and 3.6% CV 4.9, 7.2, 10.4, 15.7 and 25.6 
ng/ml, respectively. 
  For adiponectin, intra-assay precision is 3.59, 6.21 and 
1.78% CV for low (3 ng/ml), middle (6 ng/ml) and high (15 
ng/ml) concentration of adiponectin, respectively, whereas 
inter-assay precision is 9.25, 6.9 and 9.25% CV for low, 
middle and high adiponectin levels, respectively.  
  For total ghrelin, intra-assay variation is 10.0, 3.3, 7.9 
and 4.4% CV for 4 varying concentrations of ghrelin, i.e. 
1000, 1500, 2000 and 3000 pg/ml, respectively, whereas 
inter-assay variation is 14.7, 17.8, 16.0 and 16.7% CV for 
1000, 1500, 2000 and 3000 pg/ml, respectively. 
  For NPY, intra-assay precision is 3.9 and 2.6% CV   
for 57.9 and 100 pmol/L respectively, whereas inter-assay 
precision is 12.7 and 10.5% CV for 59.1 and 98.9 pmol/L, 
respectively. 
Statistical Analysis 
  Statistical analyses were performed using the SPSS   
version 13.0 software package (SPSS Inc., Chicago, USA). 
Values are expressed either as mean ± SD for parametric 
variables or as median (range) for non parametric ones. Dif-
ferences between groups at baseline, 3 and 6 months were 
analyzed by Student’s t test, Mann Whitney and 
2  test  
for parametric, non parametric continuous and categorical 
variables, respectively. Repeated measures ANOVA or the 
non-parametric alternative Friedman test was used to com-
pare related samples data throughout the study. Correlations 
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mined by Pearson r or Spearman Rho correlation analyses. 
Due to multiple comparisons, significance was set at p   
(2-tailed)  0.025 [17].  
  Males and females were considered separately because 
leptin and adiponectin levels differ significantly between 
genders [18,19]. Furthermore, patients were recruited se-
quentially and therefore we could not ensure equal gender 
distribution in both groups. In order to verify our results we 
also assessed the correlations between glucose and HbA1c 
[20], as well as between body fat and WC [21].  
RESULTS 
Results at Baseline 
Male Patients (Table 1) 
  Groups A and B were similar for hypertension, statin 
treatment, cardiovascular disease (CVD), smoking, age, 
weight, height, BMI, WC, duration of diabetes, systolic 
blood pressure (SBP), diastolic blood pressure (DBP), WCC, 
uric acid, HDL-C, LDL-C, AST, ALT, CK, Cr, leptin, adi-
ponectin, ghrelin, NPY, MDRD eGFR and Cockroft-Gault 
creatinine clearance. However, in group B body fat was sig-
nificantly higher (p = 0.005), whereas TC (p = 0.005), TG (p 
= 0.012) and gamma-GT (p = 0.012) were significantly 
lower compared with group A.  
Female Patients (Table 2) 
  Groups A and B were similar for hypertension, statin 
treatment, CVD, smoking, age, weight, height, WC, duration 
of diabetes, SBP, WCC, uric acid, TG, HDL-C, LDL-C, 
AST, ALT, CK, gamma-GT, Cr, leptin, adiponectin, MDRD 
eGFR and Cockroft-Gault creatinine clearance. However, in 
group B BMI (p = 0.009) and body fat (p < 0.001) were sig-
nificantly higher, whereas DBP (p = 0.013), TC (p = 0.022), 
ghrelin (p = 0.019) and NPY (p = 0.021) were significantly 
lower compared with group A. 
  For both genders we did not compare glucose and HbA1c 
values at baseline since we defined group A as uncontrolled 
and group B as well-controlled patients with T2DM.  
Results at 3 Months 
Male Patients (Table 3) 
  NPY levels were higher in group B compared with group 
A (p = 0.017).  
Female Patients (Table 4) 
  Body fat was higher (p = 0.004) and HDL-C levels were 
lower (p = 0.001) in group B compared with group A. 
Results at 6 Months 
Male Patients (Table 5) 
  Fasting glucose (p = 0.005) and leptin levels were lower 
(p = 0.003) in group B compared with group A.  
Female Patients (Table 6) 
  Ghrelin levels were lower (p < 0.001) and NPY levels 
were higher (p = 0.01) in group B compared with group A. 
Changes Throughout the Study in Groups A and B 
Male Patients 
  In group A weight (p < 0.001), BMI (p < 0.001), leptin  
(p < 0.001) and adiponectin levels (p = 0.008) increased   
significantly, whereas fasting glucose (p < 0.001), HbA1c  
(p < 0.001) and NPY levels (p < 0.001) decreased signifi-
cantly. No differences were observed in group B male   
patients. 
Female Patients 
  In group A weight (p = 0.001), BMI (p< 0.001), HDL-C 
(p = 0.002) and leptin levels (p = 0.003) increased signifi-
cantly, whereas fasting glucose (p < 0.001), HbA1c (p < 
0.001), DBP (p = 0.003), TG (p = 0.006) and NPY levels (p 
< 0.001) decreased significantly. In group B female patients, 
body fat (p = 0.002), AST (p = 0.012) and ghrelin levels (p < 
0.001) were significantly reduced. 
Correlations 
  Leptin levels significantly correlated with WC and   
body fat in all patient groups, except group B male patients 
(Table 7). 
  As expected, glucose correlated significantly with HbA1c 
in all groups and at all times (p = 0.019 to <0.0001), except 
for group A females at baseline and 3 months. Furthermore, 
body fat correlated significantly with WC in all groups and 
at all times (p = 0.01 to <0.0001), except group B male pa-
tients (Table 7). 
DISCUSSION 
  Leptin levels were higher in females compared with 
males in each group, at all sampling points during the study 
(p 0.001 for all comparisons). These findings are consistent 
with previous results in T2DM patients on various hypogly-
caemic treatments [18]. Adiponectin concentrations were 
non-significantly higher in females in each group, at baseline 
and at 6 months. Circulating adiponectin levels are reported 
to be higher in females with or without DM in some but not 
all studies [19, 22, 23]. No significant gender differences in 
ghrelin concentrations were found in each group at all sam-
pling points during the study. This is in agreement with re-
ports in nondiabetic individuals [24], although higher circu-
lating ghrelin concentrations in nondiabetic females have 
been documented [25]; data in T2DM patients are lacking. 
NPY levels did not differ significantly between genders in 
each group at all times during the study. No literature regard-
ing gender differences for NPY were found. 
  Some of the differences we observed between groups at 
baseline may be attributed to the uncontrolled patients being 
more concerned about their lifestyle (e.g. weight). Uncon-
trolled group A females had significantly higher baseline 
ghrelin levels compared with well-controlled group B female 
patients (p = 0.019). In contrast, others reported that patients 
with T2DM had lower ghrelin levels when long-term gly-
caemic control was poor [26]. The observed lower baseline 
ghrelin concentrations in group B females may be attributed 
to their higher BMI and body fat compared with group A 
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Table 1.  Baseline Clinical and Fasting Laboratory Characteristics of Male Patients with type 2 Diabetes Mellitus 
  Group A (n=26)  Group B (n=15)  p 
Hypertension (%)  57.7 73.3 ns 
Statin use (%)  42.3 53.3 ns 
CVD (%)  42.3 20  ns 
Smoking (%)  38.5 20  ns 
Age (years)  66.9±8.1 68.1±6.8 ns 
Weight (kg)  74.6±14 77.4±9.5  ns 
Height (m)  1.7±0.1 1.7±0.1 ns 
BMI (kg/m
2)  26.4±4.1 27.6±3.2 ns 
Waist circumference (cm)  97.9±12.8 97.3±7.8  ns 
Body fat (%)  31.8±9.6 41.3±10  0.005 
Duration of diabetes (years)  12.8±7.5 10.9±9.5 ns 
SBP (mmHg)  131.5±22 136.3±18.1  ns 
DBP(mmHg)  78.5±15.2 76.3±11.1 ns 
WCC (x10
3/μl)  7319±1805 6311±1896 ns 
Uric acid (mg/dl)  5.3±1.5 5.6±1.2 ns 
TC (mg/dl)  193±36 157±37 0.005 
TG (mg/dl)  172±91 109±34 0.012 
HDL-C (mg/dl)  47±12 45±10 ns 
LDL-C (mg/dl)  112±32 90±30  ns 
AST (u/l)  20±10 22±12 ns 
ALT (u/l)  22±12 45±81 ns 
CK (u/l)  69±39 135±159  ns 
Gamma-GT (u/l)  31 
(12-138) 
19 
(8-304) 
0.012 
Glucose (mg/dl)  216±79 131±25 N/A 
HbA1c (%)  9.8±1.7 6±0.9  N/A 
Cr (mg/dl)  1±0.3 0.9±0.2  ns 
Leptin (ng/ml)  7.6±7.4 4.3±2.3 ns 
Adiponectin (μg/ml)  11.5±8.4 15.6±9.7 ns 
Ghrelin (pg/ml)  874±292 810±176 ns 
NPY (pmol/L)  156.5±57.8 127.4±29.5 ns 
MDRD eGFR (mL/min/1.73m
2)  84.5±22.8 96.6±22.4 ns 
Cockroft-Gault creatinine clearance (mL/min)  79.9±26.2 91.6±22.6 ns 
CVD: cardiovascular disease (coronary heart disease and/or stroke); BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WCC: white cell count; TC: 
total cholesterol; TG: triglyceride; HDL-C: high density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; AST: aspartate transaminase; ALT: alanine transa-
minase; CK: creatine kinase; gamma-GT: gamma glutamyl transpeptidase; Cr: creatinine; NPY: neuropeptide Y; MDRD: modification of diet in renal disease; eGFR: estimated 
glomerular filtration rate; N/A: not applicable. 
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Table 2.  Baseline Clinical and Fasting Laboratory Characteristics of Female Patients with Type 2 Diabetes Mellitus 
  Group A (n=19)  Group B (n=30)  p 
Hypertension (%)  63.2 83.3 ns 
Statin use (%)  52.6 56.7 ns 
CVD (%)  21.1 16.7 ns 
Smoking (%)  31.6 13.3 ns 
Age (years)  61.8±11.4 64.5±6.6  ns 
Weight (kg)  69.1±19.4 75.3±14.2 ns 
Height (m)  1.6±0.1 1.6±0.1 ns 
BMI (kg/m
2)  27.1±7.2 31±4.9  0.009 
Waist circumference (cm)  96.6±16.8 105.8±13  ns 
Body fat (%)  41±7.9 50.7±7.9  <0.001 
Duration of diabetes (years)  11.3±6 9.7±6.8  ns 
SBP (mmHg)  141.1±19.8 136.3±16.6 ns 
DBP(mmHg)  85.8±13.1 75.7±11.4 0.013 
WCC (x10
3/μl)  7799±3277 7132±1551 ns 
Uric acid (mg/dl)  4.5±1.6 5.5±1.4 ns 
TC (mg/dl)  222±45 192±41 0.022 
TG (mg/dl)  160  
(69-620) 
129 
(69-542) 
ns 
HDL-C (mg/dl)  58±18 49±12 ns 
LDL-C (mg/dl)  125±41 113±33 ns 
AST (u/l)  20±12 21±6  ns 
ALT (u/l)  24±17 24±15 ns 
CK (u/l)  60±27 82±36 ns 
Gamma-GT (u/l)  17 
(12-120) 
15 
(10-53) 
ns 
Glucose (mg/dl)  232±59 136±35 N/A 
HbA1c (%)  10.3±1.7 6.2±0.7  N/A 
Cr (mg/dl)  0.8±0.3 0.8±0.2 ns 
Leptin (ng/ml)  14.3±8.8 17.8±8.1 ns 
Adiponectin (μg/ml)  15.9±8.4 16.8±11.1  ns 
Ghrelin (pg/ml)  934±245 809±314 0.019 
NPY (pmol/L)  186.1±71.9 140.9±45.7 0.021 
MDRD eGFR (mL/min/1.73m
2)  82.8±30.9 88.6±28.2 ns 
Cockroft-Gault creatinine clearance (mL/min)  87.2±54.5 95.8±38.4 ns 
For abbreviations see Table 1. 
BMI and body fat in T2DM patients [27]. However, ghrelin 
levels remained significantly higher in group A females 
compared with group B females (p < 0.001) 6 months after 
initiation of insulin therapy, even though BMI and body fat 
became similar between these groups.  Leptin, Adiponectin, Ghrelin, NPY and Glycaemic Control  The Open Cardiovascular Medicine Journal, 2011, Volume 5    141 
  Group A males had higher leptin levels than group B 
males at 6 months. This agrees with previous reports of 
higher leptin concentrations in T2DM patients on insulin 
therapy compared with those on other hypoglycaemic treat-
ment [18].  
  Group A females had significantly higher HDL-C con-
centrations compared with group B females at 3 months (p = 
0.001). This difference may be attributed to the insulin-
induced improvement of HbA1c observed at 3 months, as 
good glycaemic control is associated with increased HDL-C 
levels in T2DM patients [28]. However, no similar results 
were observed in our male patients. 
  In the present study, after 6 months of insulin therapy, 
weight, BMI and leptin levels significantly increased, 
whereas fasting glucose, HbA1c and NPY levels significantly 
decreased in both males and females. These insulin-
associated changes have been reported [29-32], although 
without considering genders separately.  
 Aas  et al., suggested that, since the increase in leptin 
concentrations precedes weight gain during insulin therapy, 
insulin per se and not increased fat mass is responsible for 
the observed changes [30]. The sustained rise in body weight 
despite the significant simultaneous increase in leptin levels 
may be explained by leptin resistance in diabetic patients 
[32].  
  Adiponectin levels significantly increased only in insu-
lin-treated males. Similarly, Miyashita et al., [33] reported 
that adiponectin concentrations increased in patients with 
Table 3.  Fasting Laboratory and Other Characteristics of Male Patients with Type 2 Diabetes Mellitus at 3 Months 
  Group A (n=26)  Group B (n=15)  p 
Weight (kg)  76.1±14.4 77.5±9.4  ns 
BMI (kg/m
2)  26.9±4.2 27.7±3.3 ns 
Waist circumference (cm)  96.7±12.4 98.1±8.3  ns 
Body fat (%)  34.5±13 37.5±6.8  ns 
SBP (mmHg)  137.7±18.2 133.7±12.9 ns 
DBP(mmHg)  76.9±12.1 76.7±10.5 ns 
WCC (x10
3/μl)  6782±2174 6953±1472 ns 
Uric acid (mg/dl)  5.7±1.5 5.7±0.9 ns 
TC (mg/dl)  190±49 173±28 ns 
TG (mg/dl)  129±58 136±53 ns 
HDL-C (mg/dl)  48±10 48±11 ns 
LDL-C (mg/dl)  116±40 97±23  ns 
AST (u/l)  19±5 21±9 ns 
ALT(u/l))  19±7 23±11  ns 
CK (u/l)  106±60 99±86  ns 
Gamma-GT (u/l)  30 
(10-75) 
17 
(10-475) 
ns 
Glucose (mg/dl)  151±51 123±31 ns 
HbA1c (%)  7±1.6 5.8±0.9  N/A 
Cr (mg/dl)  0.9±0.3 0.9±0.2 ns 
Leptin (ng/ml)  10.4±7.7 6.7±4.3  ns 
Adiponectin (μg/ml)  15±11.6 11.7±7.3  ns 
Ghrelin (pg/ml)  933±574 801±227 ns 
NPY (pmol/L)  111.7±26.3 133.4±27.6 0.017 
MDRD eGFR (mL/min/1.73m
2)  87.1±24.7 95.5±27.1 ns 
Cockroft-Gault creatinine clearance (mL/min)  84.7±32.9 90.8±25.5 ns 
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T2DM after initiation of insulin treatment (twice-daily 
biphasic insulin analogue). In contrast, Jacob et al., reported 
a non significant trend for a reduction in adiponectin levels 
in T2DM patients on insulin monotherapy or insulin plus 
metformin [29]. These discrepancies could be explained   
by differences in sample size and HbA1c values achieved. 
Furthermore, neither Miyashita et al., [33] nor Jacob et al., 
[29] analyzed their results according to gender.  
  Ghrelin levels did not change significantly in the insulin 
monotherapy groups, as previously reported [31]. In contrast, 
Jacob  et al., documented significant decreases in ghrelin 
concentrations after initiation of insulin therapy in T2DM 
patients [29].  
  It has been demonstrated that NPY is expressed and se-
creted by adipose tissue and that peripherally administered 
insulin stimulates the release of adipogenic NPY [34]. As 
NPY has been reported to exert antilipolytic properties, hy-
perinsulinemia may lead to an increase in adiposity via ele-
vated circulating NPY levels [34]. These interactions may 
partly explain the hyperinsulinemia-related weight gain. In 
contrast, in the present study, NPY levels significantly de-
creased in both males and females following the initiation of 
insulin therapy. Leptin has been reported to suppress the 
hypothalamic expression of NPY [35]; thus increased leptin 
levels may lead to reductions in NPY concentrations in both 
the hypothalamus and the circulation. It should be noted that 
we do not know if circulating NPY levels represent changes 
in the hypothalamus. There is evidence that NPY can cross 
the blood brain barrier [36] but this has only been demon-
strated in animals. The fall in NPY levels observed in our 
study may reflect a complex interaction of several factors 
Table 4.  Fasting Laboratory and Other Characteristics of Female Patients with type 2 Diabetes Mellitus at 3 Months 
  Group A (n=19)  Group B (n=30)  p 
Weight (kg)  72.6±19.9 75.3±13.9  ns 
BMI (kg/m
2)  28.5±7.4 31.1±4.9  ns 
Waist circumference (cm)  100.9±17.2 104.9±12.1  ns 
Body fat (%)  39.2±8.6 46.3±6.2  0.004 
SBP (mmHg)  136.3±22.1 181.8±270.3  ns 
DBP(mmHg)  75.5±13.8 77.3±12  ns 
WCC (x10
3/μl)  6840±1693 7387±1515  ns 
Uric acid (mg/dl)  4.9±1.3 5.6±1.3  ns 
TC (mg/dl)  196±40 196±42  ns 
TG (mg/dl)  125±57 168±94  ns 
HDL-C (mg/dl)  65±18 50±12  0.001 
LDL-C (mg/dl)  106±34 113±30  ns 
AST (u/l)  23±10 20±6  ns 
ALT(u/l)  25±15 22±9  ns 
CK (u/l)  83±34 97±73  ns 
Gamma-GT (u/l)  15 
(7-292) 
16 
(10-79) 
ns 
Glucose (mg/dl)  141±50 141±34  ns 
HbA1c (%)  7.2±1.4 6.2±0.8  N/A 
Cr (mg/dl)  0.8±0.2 0.8±0.2  ns 
Leptin (ng/ml)  23.4±13.5 20.2±10.9  ns 
Adiponectin (μg/ml)  12.9±11.5 11.3±5.3  ns 
Ghrelin (pg/ml)  907±284 836±315  ns 
NPY (pmol/L)  118.9±22.9 137.4±43.8  ns 
MDRD eGFR (mL/min/1.73m
2)  88.3±25.9 87.9±31.4  ns 
Cockroft-Gault creatinine clearance (mL/min)  95.7±48.3 94.1±36.2  ns 
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(e.g. leptin resistance, obesity and stress). Further research is 
needed to clarify the role of peripheral and central NPY lev-
els on appetite control. 
  Apart from appetite, NPY has been associated with in-
tense or prolonged stress, leading to vasoconstriction and 
angiogenesis [37]. Interestingly, plasma NPY concentrations 
were reported to be increased due to enhanced sympathetic 
activation in stress-related cardiac conditions [38]. 
  Therefore, an increase in circulating NPY levels cannot 
be attributed separately to changes in nutritional or stress 
status.  
  Of note, in patients on hemodialysis, plasma NPY con-
centrations were elevated due to both a poor state of nour-
ishment and fluid volume overload-induced stress [39]. 
  Body fat has been proposed as the best predictor of leptin 
levels in humans independently of gender [40]. In the present 
study a non significant increase in the percentage of body fat 
was observed following insulin therapy, as reported by oth-
ers [29]. Interestingly, a significant insulin-related increase 
in both subcutaneous fat area and fat mass was also observed 
in T2DM patients [29, 30]. These discrepancies may be at-
tributed to differences in methodology (e.g. definition of 
body fat).  
  In our study, leptin levels correlated with body fat (%) 
and WC in all groups, except group B males. Similarly, WC 
correlated with leptin concentrations in Asian-Indian patients 
with impaired glucose tolerance or T2DM [41, 42]. In the 
present study, changes in leptin levels did not correlate with 
HbA1c, as reported by Aas et al., [30].  
Table 5.  Fasting Laboratory and Other Characteristics of Male Patients with Type 2 Diabetes Mellitus at 6 Months 
  Group A (n=26)  Group B (n=15)  p 
Weight (kg)  78.2±14.6 77.4±9.6  ns 
BMI (kg/m
2)  27.7±4.3 27.6±3.4 ns 
Waist circumference (cm)  100.5±12.1 97.1±9.1  ns 
Body Fat (%)  34.6±10.1 35.9±8  ns 
SBP (mmHg)  136.4±18.5 129.3±16.1 ns 
DBP(mmHg)  78.9±12.8 73±5.9  ns 
WCC (x10
3/μl)  7425±1906 6269±1389 ns 
Uric acid (mg/dl)  5.5±1.7 5.8±0.9 ns 
TC (mg/dl)  188±61 171±32 ns 
TG (mg/dl)  136±58 130±76 ns 
HDL-C (mg/dl)  45±10 47±8  ns 
LDL-C (mg/dl)  108±33 97±23  ns 
AST (u/l)  21±6 25±9 ns 
ALT(u/l)  20±8 26±9 ns 
CK (u/l)  114±53 128±150  ns 
Gamma-GT (u/l)  26 
(10-200) 
18 
(8-494) 
ns 
Glucose (mg/dl)  158±52 119±19 0.005 
HbA1c (%)  6.8±1.5 5.7±0.8 N/A 
Cr (mg/dl)  1±0.3 0.9±0.2  ns 
Leptin (ng/ml)  10.6±7.3 4.5±2.6  0.003 
Adiponectin (μg/ml)  17.5±9.2 18.7±18.2  ns 
Ghrelin (pg/ml)   818±255 662±285 ns 
NPY (pmol/L)  85.8±30.9 108±36.7  ns 
MDRD eGFR (mL/min/1.73m
2)  83.5±20.4 93.8±27  ns 
Cockroft-Gault creatinine clearance (mL/min)  82.8±25.5 89.7±25.6 ns 
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  Patients on OHAs did not show any change in weight or 
leptin levels throughout the study, as previously reported 
[30]. Group B females were the only patients to show sig-
nificant reduction in both ghrelin levels and body fat. These 
results may be because they had the highest body fat (50.7 ± 
7.9%) at baseline and the greatest reduction (33%) in ghrelin 
levels throughout the study compared with the other groups. 
  Throughout the study, TG levels significantly decreased 
(p = 0.006) and HDL-C levels significantly increased (p = 
0.002) only in group A females. These results may be attrib-
uted to the insulin-induced improvement of HbA1c, as good 
glycaemic control exerts beneficial effects on lipids in 
T2DM patients [28].  
  DBP significantly decreased in group A females 6 
months after initiation of insulin therapy (p = 0.003). In this 
context, others [43] reported a significant positive associa-
tion of mean HbA1c and DBP in patients with type 1 diabetes 
mellitus (T1DM); no data were found for T2DM patients.  
  Renal function indices did not change significantly 
throughout the study in all groups. However, all our patients 
had normal kidney function. In contrast, abnormal baseline 
GFR values in patients with T1DM improved significantly 
following intensive insulin treatment [44]; no data were 
found for T2DM patients.  
  Several drugs frequently prescribed to diabetic patients 
have been shown to influence leptin, adiponectin and/or 
ghrelin levels [45]. In detail, OHAs have been reported to 
differentially influence plasma levels of leptin, adiponectin 
and ghrelin [11-14, 46-48], whereas there were no reports for 
NPY. Antihypertensive agents were shown to either increase 
Table 6.  Fasting Laboratory and Other Characteristics of Female Patients with Type 2 Diabetes Mellitus at 6 Months 
  Group A (n=19)  Group B (n=30)  p 
Weight (kg)  73.3±21.2 76.2±14.4 ns 
BMI (kg/m
2)  28.8±7.9 31.4±5.1 ns 
Waist circumference (cm)  101±18.1 105.7±12.8  ns 
Body Fat (%)  41.4±13.3 47.5±7.4  ns 
SBP (mmHg)  139.7±24.6 139.5±11.7 ns 
DBP (mmHg)  79.2±12.6 78.6±8.3  ns 
WCC (x10
3/μl)  7186±1859 7418±1671 ns 
Uric acid (mg/dl)  4.8±1.4 5.4±1.4 ns 
TC (mg/dl)  198±35 191±34 ns 
TG (mg/dl)  145±79 161±71 ns 
HDL-C (mg/dl)  60±19 52±13 ns 
LDL-C (mg/dl)  109±35 115±54 ns 
AST (u/l)  22±9 17.2±6.9  ns 
ALT(u/l)  23±11 22±9  ns 
CK (u/l)  103±71 87±53  ns 
Gamma-GT (u/l)  19 
(9-299) 
16 
(7-56) 
ns 
Glucose (mg/dl)  142±55 139±35 ns 
HbA1c (%)  6.9±1.5 6.3±1.1 ns 
Cr (mg/dl)  0.8±0.2 0.8±0.2 ns 
Leptin (ng/ml)  23.3±12.8 17.4±7.9  ns 
Adiponectin (μg/ml)  18.3±14.1 24.9±19.7 ns 
Ghrelin (pg/ml)   874±346 542±312 <0.001 
NPY (pmol/L)  96.9±31.1 131.1±56.9  0.01 
MDRD eGFR (mL/min/1.73m
2)  87.6±25.4 83±25.5  ns 
Cockroft-Gault creatinine clearance (mL/min)  96.4±49.7 91.4±34.8 ns 
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[49] or reduce leptin [50] and to increase adiponectin levels 
in T2DM patients [51, 52]. No data were found regarding the 
influence of these agents on ghrelin and NPY levels in 
T2DM patients. In these patients lipid-lowering drugs were 
also reported to reduce leptin [53, 54] and increase adi-
ponectin concentrations [12, 55]. In contrast, ghrelin levels 
did not change following short-term (6 weeks) treatment 
with either atorvastatin or fenofibrate in diabetic patients 
with mixed hyperlipoproteinaemia [56]. There are no data 
concerning the effects of lipid-modifying agents on NPY 
concentrations.  
  In our study no patient was on fibrate therapy but almost 
half of them were taking statins and even more patients were 
on antihypertensive agents. The study groups did not differ 
significantly in statin and antihypertensive use and these 
treatments remained unchanged throughout the study. Never-
theless, the use of different drugs in our patients is a limita-
tion of our study as is the small sample size which did not 
allow multivariate analysis. However, other studies in this 
field [29-33] had similar patient numbers and did not analyze 
their results by gender. Furthermore, the measured parame-
ters are interrelated and the influence of each individual fac-
tor on insulin-related body weight gain is difficult to iden-
tify. 
CONCLUSIONS 
  In the present study, initiation of insulin treatment was 
associated with a significant increase in leptin levels and a 
significant decrease in NPY levels in both genders. These 
effects should have suppressed appetite and reduced food 
consumption, leading to weight loss. In contrast, all insulin-
treated patients gained weight, possibly due to other mecha-
nisms such as the anabolic effects of insulin, stimulation of 
lipogenesis, suppression of hepatic glucose production, re-
duction of basal metabolic rate and elimination of glyco-
suria. It is also possible that leptin resistance may be partly 
responsible for the observed weight increase. 
  In general, changes in leptin, adiponectin and NPY levels 
may occur following insulin-induced improved glycaemic 
control. These changes may be influenced by several vari-
ables, including gender, weight, body fat and glycaemic con-
trol. The interactions between these factors were not consid-
ered in previous studies. 
  It is possible that targeting the peptides measured in this 
study could influence weight gain after insulin treatment.  
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